Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hi-Tech CEO Could Face Jail For Violating Court Order To Recall Weight Loss Products

This article was originally published in The Tan Sheet

Executive Summary

A federal judge soon will decide whether Hi-Tech Pharmaceuticals CEO Jared Wheat goes to jail for failing to recall weight loss products marketed with false claims. Wheat has a history of run-ins with FDA, FTC and DEA for marketing supplements adulterated with drugs and making false claims for products.

You may also be interested in...



“Mender” Supplement Firm Hopes To Reopen After Mending Its Violations

BioAnue Labs says it temporarily stopped selling its products, which FDA warned are unapproved new drugs due to claims the firm made. BioAnue’s website and others associated with the firm continue to advertise supplements under brands that include a common disease name and terms that refer to treating the condition.

“Mender” Supplement Firm Hopes To Reopen After Mending Its Violations

BioAnue Labs says it temporarily stopped selling its products, which FDA warned are unapproved new drugs due to claims the firm made. BioAnue’s website and others associated with the firm continue to advertise supplements under brands that include a common disease name and terms that refer to treating the condition.

Hi-Tech Lawsuit Calls FDA DMAA Enforcement “Bullying Tactics”

Hi-Tech Pharmaceuticals files a lawsuit in federal court after receiving an administrative detention order from FDA to stop distributing its DMAA-containing products. The firm argues FDA should conduct a rulemaking to propose banning DMAA rather than ordering firms to stop using it.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS107112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel